Symbols / AIM $0.43 +5.82% AIM ImmunoTech Inc.

Healthcare • Biotechnology • United States • ASE
AIM Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Thomas K. Equels Esq., J.D., M.S.
Exch · Country ASE · United States
Market Cap 6.78M
Enterprise Value 3.91M
Income -13.96M
Sales 88.00K
FCF (ttm) -11.97M
Book/sh -3.19
Cash/sh 0.37
Employees 19
Insider 10d —
IPO Jul 12, 1996
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.30
PEG 0.71
P/S 77.09
P/B -0.14
P/C —
EV/EBITDA -0.34
EV/Sales 44.44
Quick Ratio 0.49
Current Ratio 0.53
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -8.62
EPS next Y -1.47
EPS Growth —
Revenue Growth -53.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) 2026-05-15
ROA -101.32%
ROE —
ROIC —
Gross Margin -45.46%
Oper. Margin -140.57%
Profit Margin 0.00%
Shs Outstand 15.60M
Shs Float 7.99M
Insider Own 1.98%
Instit Own 2.48%
Short Float 3.79%
Short Ratio 1.01
Short Interest 303.17K
52W High 19.74
vs 52W High -97.80%
52W Low 0.24
vs 52W Low 81.21%
Beta 1.24
Impl. Vol. —
Rel Volume 0.41
Avg Volume 11.60M
Volume 4.75M
Target (mean) $10.00
Tgt Median $10.00
Tgt Low $10.00
Tgt High $10.00
# Analysts 1
Recom None
Prev Close $0.41
Price $0.43
Change 5.82%
About

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.00
Mean price target
2. Current target
$0.43
Latest analyst target
3. DCF / Fair value
$-13.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.43
Low
$10.00
High
$10.00
Mean
$10.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-10 main Ascendiant Capital Buy → Buy $10
2025-12-08 main Ascendiant Capital Buy → Buy $22
2025-10-03 main Ascendiant Capital Buy → Buy $24
2024-12-10 main Ascendiant Capital Buy → Buy $5
2024-10-22 main Maxim Group Buy → Buy $1
2024-09-03 main Ascendiant Capital Buy → Buy $5
2019-10-10 up Maxim Group Hold → Buy —
News
RSS: Latest AIM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-12 CHEMEROW DAVID I Director — 25,000 — —
2026-03-12 EQUELS THOMAS K Chief Executive Officer — 25,000 — —
2026-02-05 CHEMEROW DAVID I Director — 2,800 $1.23 $3,444
2025-06-13 EQUELS THOMAS K Chief Executive Officer — 107 $7.70 $824
2025-06-12 EQUELS THOMAS K Chief Executive Officer — 103 $0.08 $9
2025-04-11 MITCHELL WILLIAM M Director — 196,851 $0.03 $5,000
2025-04-11 KELLNER TED D Director — 1,968,504 $0.03 $50,000
2025-04-11 EQUELS THOMAS K Chief Executive Officer — 1,968,504 $0.03 $50,000
2025-04-11 KELLNER TED D Director — 1,968,504 $0.03 $50,000
2025-04-04 RODINO PETER W III Chief Operating Officer — 500 $0.09 $44
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.09
-48.24%
0.17
-15.84%
0.20
+43.26%
0.14
Operating Revenue
0.09
-48.24%
0.17
-15.84%
0.20
+43.26%
0.14
Cost Of Revenue
0.13
+312.90%
0.03
-26.19%
0.04
0.00
Reconciled Cost Of Revenue
0.13
+312.90%
0.03
-26.19%
0.04
0.00
Gross Profit
-0.04
-128.78%
0.14
-13.13%
0.16
+13.48%
0.14
Operating Expense
11.62
-41.62%
19.91
-37.93%
32.08
+59.87%
20.06
Research And Development
3.92
-36.68%
6.20
-43.35%
10.94
+56.49%
6.99
Selling General And Administration
7.70
-43.85%
13.71
-35.12%
21.14
+61.67%
13.07
General And Administrative Expense
7.70
-43.85%
13.71
-35.12%
21.14
+61.67%
13.07
Other Gand A
7.70
-43.85%
13.71
-35.12%
21.14
+61.67%
13.07
Total Expenses
11.75
-41.07%
19.94
-37.91%
32.12
+60.08%
20.06
Operating Income
-11.66
+41.01%
-19.77
+38.05%
-31.92
-60.20%
-19.92
Total Operating Income As Reported
-11.66
+41.01%
-19.77
+38.05%
-31.92
-60.20%
-19.92
EBITDA
-12.94
+21.55%
-16.49
+42.60%
-28.72
-46.05%
-19.67
Normalized EBITDA
-8.70
+45.39%
-15.94
+44.93%
-28.94
-60.56%
-18.03
Reconciled Depreciation
0.21
-14.63%
0.25
+3.36%
0.24
-7.03%
0.26
EBIT
-13.15
+21.45%
-16.73
+42.22%
-28.96
-45.37%
-19.92
Total Unusual Items
-4.23
-668.06%
-0.55
-352.75%
0.22
+113.28%
-1.64
Total Unusual Items Excluding Goodwill
-4.23
-668.06%
-0.55
-352.75%
0.22
+113.28%
-1.64
Special Income Charges
—
0.00
-100.00%
0.02
+500.00%
0.00
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
—
—
—
—
Write Off
—
—
—
0.00
Net Income
-13.96
+19.41%
-17.32
+40.20%
-28.96
-48.94%
-19.45
Pretax Income
-13.96
+19.41%
-17.32
+40.20%
-28.96
-48.94%
-19.45
Net Non Operating Interest Income Expense
2.37
-48.53%
4.61
+330.96%
1.07
+69.95%
0.63
Interest Expense Non Operating
0.81
+38.80%
0.58
0.00
0.00
Net Interest Income
2.37
-48.53%
4.61
+330.96%
1.07
+69.95%
0.63
Interest Expense
0.81
+38.80%
0.58
0.00
0.00
Interest Income Non Operating
3.18
-38.69%
5.19
+385.69%
1.07
+69.95%
0.63
Interest Income
3.18
-38.69%
5.19
+385.69%
1.07
+69.95%
0.63
Other Income Expense
-4.67
-116.47%
-2.15
-214.32%
1.89
+1348.34%
-0.15
Other Non Operating Income Expenses
-0.43
+73.00%
-1.60
-196.22%
1.67
+11.88%
1.49
Gain On Sale Of Security
-4.23
-668.06%
-0.55
-375.50%
0.20
+112.17%
-1.64
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.96
+19.41%
-17.32
+40.20%
-28.96
-48.94%
-19.45
Net Income From Continuing Operation Net Minority Interest
-13.96
+19.41%
-17.32
+40.20%
-28.96
-48.94%
-19.45
Net Income From Continuing And Discontinued Operation
-13.96
+19.41%
-17.32
+40.20%
-28.96
-48.94%
-19.45
Net Income Continuous Operations
-13.96
+19.41%
-17.32
+40.20%
-28.96
-48.94%
-19.45
Normalized Income
-9.73
+42.00%
-16.77
+42.53%
-29.18
-63.90%
-17.80
Net Income Common Stockholders
-13.96
+19.41%
-17.32
+40.20%
-28.96
-48.94%
-19.45
Diluted EPS
-8.62
+72.12%
-30.92
+48.42%
-59.94
-50.00%
-39.96
Basic EPS
-8.62
+72.12%
-30.92
+48.42%
-59.94
-50.00%
-39.96
Basic Average Shares
1.62
+188.95%
0.56
+15.18%
0.49
+1.12%
0.48
Diluted Average Shares
1.62
+188.95%
0.56
+15.18%
0.49
+1.12%
0.48
Diluted NI Availto Com Stockholders
-13.96
+19.41%
-17.32
+40.20%
-28.96
-48.94%
-19.45
Gain On Sale Of PPE
—
0.00
-100.00%
0.02
+500.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
5.78
-32.83%
8.61
-55.59%
19.38
-52.13%
40.49
Current Assets
3.29
-21.10%
4.18
-71.31%
14.56
-59.92%
36.32
Cash Cash Equivalents And Short Term Investments
3.05
-23.38%
3.98
-69.57%
13.07
-61.77%
34.19
Cash And Cash Equivalents
2.98
+75.49%
1.70
-68.73%
5.44
-79.90%
27.05
Other Short Term Investments
0.06
-97.28%
2.28
-70.17%
7.63
+6.92%
7.14
Receivables
0.01
0.00
-100.00%
1.18
-29.36%
1.68
Accounts Receivable
—
—
—
1.68
Other Receivables
0.01
—
1.18
-29.36%
1.68
Prepaid Assets
—
—
—
—
Other Current Assets
0.24
+21.11%
0.20
-34.11%
0.30
-33.63%
0.46
Total Non Current Assets
2.49
-43.89%
4.43
-8.15%
4.83
+15.79%
4.17
Net PPE
0.45
-38.15%
0.73
-11.89%
0.82
-19.53%
1.02
Gross PPE
1.84
-11.52%
2.08
-2.84%
2.15
-29.95%
3.06
Accumulated Depreciation
-1.40
-2.72%
-1.36
-2.80%
-1.32
+35.18%
-2.04
Properties
—
—
—
0.00
Machinery Furniture Equipment
1.47
+0.00%
1.47
+1.24%
1.45
-35.15%
2.23
Other Properties
0.38
-38.83%
0.62
-11.33%
0.70
-15.92%
0.83
Goodwill And Other Intangible Assets
1.66
-35.97%
2.59
+12.15%
2.31
+19.17%
1.94
Other Intangible Assets
1.66
-35.97%
2.59
+12.15%
2.31
+19.17%
1.94
Investments And Advances
—
—
—
—
Other Non Current Assets
0.38
-66.10%
1.11
-34.12%
1.69
+40.43%
1.20
Total Liabilities Net Minority Interest
15.56
+56.75%
9.93
+8.56%
9.15
+352.82%
2.02
Current Liabilities
6.22
-34.72%
9.54
+10.21%
8.65
+535.71%
1.36
Payables And Accrued Expenses
2.21
-68.42%
6.99
-12.81%
8.02
+578.09%
1.18
Payables
1.63
-74.46%
6.38
-0.93%
6.44
+1609.02%
0.38
Accounts Payable
1.63
-74.46%
6.38
-0.93%
6.44
+1609.02%
0.38
Current Accrued Expenses
0.58
-4.63%
0.60
-61.51%
1.57
+95.28%
0.81
Pensionand Other Post Retirement Benefit Plans Current
0.22
+21700.00%
0.00
-99.76%
0.41
+41300.00%
0.00
Current Debt And Capital Lease Obligation
3.80
+49.21%
2.55
+1041.70%
0.22
+25.28%
0.18
Current Debt
3.55
+53.84%
2.31
—
—
Other Current Borrowings
3.55
+53.84%
2.31
—
—
Current Capital Lease Obligation
0.25
+4.60%
0.24
+7.17%
0.22
+25.28%
0.18
Total Non Current Liabilities Net Minority Interest
9.34
+2264.81%
0.40
-20.20%
0.49
-24.89%
0.66
Long Term Debt And Capital Lease Obligation
1.10
+177.72%
0.40
-20.20%
0.49
-24.89%
0.66
Long Term Debt
0.93
—
—
—
Long Term Capital Lease Obligation
0.17
-56.96%
0.40
-20.20%
0.49
-24.89%
0.66
Stockholders Equity
-9.78
-640.02%
-1.32
-112.92%
10.23
-73.40%
38.47
Common Stock Equity
-9.78
-640.02%
-1.32
-113.85%
9.54
-74.73%
37.77
Capital Stock
0.00
+200.00%
0.00
-99.86%
0.74
-0.81%
0.74
Common Stock
0.00
+200.00%
0.00
-97.96%
0.05
+2.08%
0.05
Preferred Stock
0.00
0.00
-100.00%
0.69
-1.01%
0.70
Share Issued
3.07
+368.50%
0.66
+33.45%
0.49
+2.12%
0.48
Ordinary Shares Number
3.07
+368.50%
0.66
+33.45%
0.49
+2.12%
0.48
Additional Paid In Capital
431.00
+1.29%
425.50
+1.55%
419.00
+0.18%
418.27
Retained Earnings
-440.79
-3.27%
-426.83
-4.23%
-409.51
-7.61%
-380.55
Gains Losses Not Affecting Retained Earnings
—
—
—
—
Total Equity Gross Minority Interest
-9.78
-640.02%
-1.32
-112.92%
10.23
-73.40%
38.47
Total Capitalization
-8.86
-569.89%
-1.32
-112.92%
10.23
-73.40%
38.47
Working Capital
-2.93
+45.34%
-5.36
-190.77%
5.90
-83.11%
34.96
Invested Capital
-5.31
-638.78%
0.98
-89.68%
9.54
-74.73%
37.77
Total Debt
4.90
+66.47%
2.94
+309.61%
0.72
-14.22%
0.84
Net Debt
1.49
+146.04%
0.61
—
—
Capital Lease Obligations
0.42
-33.75%
0.63
-11.70%
0.72
-14.22%
0.84
Net Tangible Assets
-11.44
-192.24%
-3.92
-149.44%
7.92
-78.31%
36.53
Tangible Book Value
-11.44
-192.24%
-3.92
-154.15%
7.23
-79.82%
35.83
Current Notes Payable
—
—
—
—
Derivative Product Liabilities
8.24
0.00
—
0.00
Interest Payable
0.06
+481.82%
0.01
0.00
—
Investmentin Financial Assets
—
—
—
—
Preferred Stock Equity
—
—
0.69
-1.01%
0.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.96
+26.40%
-14.89
+29.99%
-21.27
-32.03%
-16.11
Cash Flow From Continuing Operating Activities
-10.96
+26.40%
-14.89
+29.99%
-21.27
-32.03%
-16.11
Net Income From Continuing Operations
-13.96
+19.41%
-17.32
+40.20%
-28.96
-48.94%
-19.45
Depreciation Amortization Depletion
0.21
-14.63%
0.25
+3.36%
0.24
-7.03%
0.26
Depreciation
0.04
+0.00%
0.04
-5.13%
0.04
+2.63%
0.04
Amortization Cash Flow
0.17
-17.22%
0.21
+5.03%
0.20
-8.72%
0.22
Depreciation And Amortization
0.21
-14.63%
0.25
+3.36%
0.24
-7.03%
0.26
Amortization Of Intangibles
0.17
-17.22%
0.21
+5.03%
0.20
-8.72%
0.22
Other Non Cash Items
-2.19
-462.81%
0.60
+110.80%
0.29
+142.21%
-0.68
Stock Based Compensation
0.06
-91.25%
0.69
+182.30%
0.24
-74.53%
0.95
Provisionand Write Offof Assets
—
—
—
—
Asset Impairment Charge
1.14
+2270.83%
0.05
+242.86%
0.01
0.00
Deferred Tax
—
—
0.00
-100.00%
0.20
Deferred Income Tax
—
—
0.00
-100.00%
0.20
Operating Gains Losses
4.67
+746.82%
0.55
+352.75%
-0.22
-113.26%
1.64
Gain Loss On Investment Securities
4.67
+746.82%
0.55
+375.50%
-0.20
-112.17%
1.64
Gain Loss On Sale Of PPE
—
0.00
+100.00%
-0.02
0.00
Change In Working Capital
-0.88
-396.62%
0.30
-95.85%
7.13
+638.20%
0.97
Change In Receivables
-0.01
-100.59%
1.18
+140.65%
0.49
+1505.71%
-0.04
Changes In Account Receivables
—
—
—
0.00
Change In Prepaid Assets
-0.04
-140.78%
0.10
-32.68%
0.15
+201.32%
-0.15
Change In Payables And Accrued Expense
-1.30
-3.02%
-1.26
-117.36%
7.25
+1224.68%
0.55
Change In Accrued Expense
0.42
+134.72%
-1.20
-201.53%
1.18
+220.65%
0.37
Change In Payable
-1.71
-2753.33%
-0.06
-100.99%
6.07
+3288.83%
0.18
Change In Account Payable
-1.71
-2753.33%
-0.06
-100.99%
6.07
+3288.83%
0.18
Change In Other Current Assets
0.73
+27.60%
0.58
+218.52%
-0.49
-485.54%
-0.08
Change In Other Current Liabilities
-0.27
+13.27%
-0.31
-12.77%
-0.27
-139.83%
0.69
Investing Cash Flow
1.85
-60.62%
4.71
+665.63%
-0.83
-107.57%
10.99
Cash Flow From Continuing Investing Activities
1.85
-60.62%
4.71
+665.63%
-0.83
-107.57%
10.99
Net PPE Purchase And Sale
0.00
+100.00%
-0.02
-138.30%
0.05
-98.77%
3.81
Purchase Of PPE
0.00
+100.00%
-0.02
0.00
+100.00%
-0.09
Sale Of PPE
—
0.00
-100.00%
0.05
-98.79%
3.90
Capital Expenditure
-0.38
+32.01%
-0.56
+4.96%
-0.58
-115.87%
-0.27
Net Investment Purchase And Sale
2.23
-57.60%
5.26
+1889.80%
-0.29
-104.00%
7.36
Purchase Of Investment
-0.09
+74.79%
-0.36
+77.34%
-1.59
+41.52%
-2.72
Sale Of Investment
2.32
-58.71%
5.62
+332.87%
1.30
-87.12%
10.08
Net Intangibles Purchase And Sale
-0.38
+29.74%
-0.54
+8.03%
-0.58
-216.22%
-0.18
Purchase Of Intangibles
-0.38
+29.74%
-0.54
+8.03%
-0.58
-216.22%
-0.18
Financing Cash Flow
10.39
+61.20%
6.44
+1228.66%
0.48
+506.25%
0.08
Cash Flow From Continuing Financing Activities
10.39
+61.20%
6.44
+1228.66%
0.48
+506.25%
0.08
Net Issuance Payments Of Debt
2.09
-7.07%
2.25
0.00
0.00
Issuance Of Debt
2.75
+10.00%
2.50
0.00
—
Repayment Of Debt
-0.66
-162.95%
-0.25
0.00
0.00
Long Term Debt Issuance
2.75
+10.00%
2.50
0.00
—
Long Term Debt Payments
-0.66
-162.95%
-0.25
0.00
0.00
Net Long Term Debt Issuance
2.09
-7.07%
2.25
0.00
0.00
Net Common Stock Issuance
8.30
+830.27%
0.89
+83.92%
0.48
+506.25%
0.08
Proceeds From Stock Option Exercised
0.00
-100.00%
3.30
0.00
—
Changes In Cash
1.28
+134.35%
-3.74
+82.71%
-21.61
-328.85%
-5.04
Beginning Cash Position
1.70
-68.73%
5.44
-79.90%
27.05
-15.70%
32.09
End Cash Position
2.98
+75.49%
1.70
-68.73%
5.44
-79.90%
27.05
Free Cash Flow
-11.34
+26.61%
-15.44
+29.32%
-21.85
-33.41%
-16.38
Change In Interest Payable
—
—
—
—
Common Stock Issuance
8.30
+830.27%
0.89
+83.92%
0.48
+506.25%
0.08
Issuance Of Capital Stock
8.30
+830.27%
0.89
+83.92%
0.48
+506.25%
0.08
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category